{"title":"在新诊断的急性髓性白血病中远离标准诱导。","authors":"Maire Okoniewski, Jesus Gonzalez Lugo, Tara L Lin","doi":"10.1200/EDBK-25-473646","DOIUrl":null,"url":null,"abstract":"<p><p>Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of targeted agents against leukemia driver mutations have revolutionized therapy for subsets of patients. In addition, the development of more effective and less toxic induction regimens with a backbone of venetoclax and hypomethylating agents is a real advance in therapy for older or less fit patients with AML. In this review, we will describe improved outcomes for alternate induction strategies, results with combinations of targeted agents and standard chemotherapy, and the important role of complete diagnostic testing and clinical trials to improve outcomes for patients with AML.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473646"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia.\",\"authors\":\"Maire Okoniewski, Jesus Gonzalez Lugo, Tara L Lin\",\"doi\":\"10.1200/EDBK-25-473646\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of targeted agents against leukemia driver mutations have revolutionized therapy for subsets of patients. In addition, the development of more effective and less toxic induction regimens with a backbone of venetoclax and hypomethylating agents is a real advance in therapy for older or less fit patients with AML. In this review, we will describe improved outcomes for alternate induction strategies, results with combinations of targeted agents and standard chemotherapy, and the important role of complete diagnostic testing and clinical trials to improve outcomes for patients with AML.</p>\",\"PeriodicalId\":37969,\"journal\":{\"name\":\"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\",\"volume\":\"45 3\",\"pages\":\"e473646\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/EDBK-25-473646\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/EDBK-25-473646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia.
Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of targeted agents against leukemia driver mutations have revolutionized therapy for subsets of patients. In addition, the development of more effective and less toxic induction regimens with a backbone of venetoclax and hypomethylating agents is a real advance in therapy for older or less fit patients with AML. In this review, we will describe improved outcomes for alternate induction strategies, results with combinations of targeted agents and standard chemotherapy, and the important role of complete diagnostic testing and clinical trials to improve outcomes for patients with AML.
期刊介绍：
The Ed Book is a National Library of Medicine–indexed collection of articles written by ASCO Annual Meeting faculty and invited leaders in oncology. Ed Book was launched in 1985 to highlight standards of care and inspire future therapeutic possibilities in oncology. Published annually, each volume highlights the most compelling research and developments across the multidisciplinary fields of oncology and serves as an enduring scholarly resource for all members of the cancer care team long after the Meeting concludes. These articles address issues in the following areas, among others: Immuno-oncology, Surgical, radiation, and medical oncology, Clinical informatics and quality of care, Global health, Survivorship.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
